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ABSTRACT
Background: Multiple-breath washout (MBW)-derived lung clearance index (LCI) detects early cystic
fibrosis (CF) lung disease. LCI was used as an end-point in single- and multicentre settings at highly
experienced MBW centres in preschool children. However, multicentre feasibility of MBW in children
aged 2–6 years, including centres naïve to this technique, has not been determined systematically.
Methods: Following central training, 91 standardised nitrogen MBW investigations were performed in
74 awake preschool children (15 controls, 46 with CF, and 13 with other lung diseases), mean age
4.6±0.9 years at investigation, using a commercially available device across five centres in Germany (three
experienced, two naïve to the performance in awake preschool children) with central data analysis. Each
MBW investigation consisted of several measurements.
Results: Overall success rate of MBW investigations was 82.4% ranging from 70.6% to 94.1% across study
sites. The number of measurements per investigation was significantly different between sites ranging from
3.7 to 6.2 (p<0.01), while the mean number of successful measurements per investigation was comparable
with 2.1 (range, 1.9 to 2.5; p=0.46). In children with CF, the LCI was increased (median 8.2, range,
6.7–15.5) compared to controls (median 7.3, range 6.5–8.3; p<0.01), and comparable to children with
other lung diseases (median 7.9, range, 6.6–13.9; p=0.95).
Conclusion: This study demonstrates that multicentre MBW in awake preschool children is feasible, even
in centres previously naïve, with central coordination to assure standardised training, quality control and
supervision. Our results support the use of LCI as multicentre end-point in clinical trials in awake
preschoolers with CF.
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Lung disease remains the leading cause of morbidity and mortality in patients with cystic fibrosis (CF) and
starts in the first months of life. Therefore, early diagnosis and therapeutic intervention may be most
beneficial [1–6]. To determine efficacy of new therapies that address early CF lung disease in multicentre
studies, sensitive, quantitative noninvasive end-points are needed to detect early lung abnormalities and
disease progression in preschool children with CF [7]. Recently, we demonstrated that studies of lung
morphology and function by lung imaging using magnetic resonance imaging (MRI) and multiple-breath
washout (MBW) are feasible in sedated infants and preschool children in a multicentre setting [8, 9]. Both
methods were previously shown to detect early abnormalities in CF lung disease such as increased
ventilation inhomogeneity as determined by the MBW-derived lung clearance index (LCI) and structural
changes and perfusion deficits detected by lung MRI [10–12].
The sensitivity of the LCI to detect response to therapy with a spectrum of interventions including inhaled
hypertonic saline, inhaled DNase, CF transmembrane conductance regulator (CFTR) modulators and
antibiotic therapy for pulmonary exacerbation, has been demonstrated for several paediatric age groups
from infancy to school-age, including multicentre studies with performance of MBW either in sedated
infants and preschool children or in awake children 3 years and older at centres highly experienced in this
technique in the corresponding age group [6, 10, 13–17]. In addition, observational studies across two
MBW-experienced sites of the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST
CF) and an observational study across three MBW-experienced North American CF centres used the LCI
as end-point in preschool children [11, 18]. Recently, the success of an approach using standardised
training and central quality control on feasibility of multicentre MBW in school-age children including
centres previously naïve to the technique in the age group of children 6–11 years old has been
demonstrated [19].
However, the multicentre feasibility of MBW in awake preschool children with CF including study centres
naïve to the technique in that age group has not been studied systematically. In a previous study in infants
and toddlers, we were able to demonstrate feasibility of sulfur hexafluoride (SF6)-MBW in sedated children
at three centres following dedicated training of the sites’ staff, and including central reading and
supervision [8]. MBW in preschool children can also be performed by inhalation of 100% oxygen to
washout nitrogen (N2) from the lungs instead of using SF6 as tracer gas, as alterations of the breathing
pattern induced by exposure to pure oxygen found in infants seem to be smaller in this age group [20–22].
However, the age-dependent ability to cooperate is limited in preschool children making the investigations
more demanding, which may hamper the feasibility of multicentre trials in this age group.
We hypothesised that our previous approach of central training and quality control [8] would lead to
acceptable MBW success rates at centres with and without prior experience in performance of MBW in
preschool children. The aim of this study was therefore to implement and validate a standardised
multicentre N2-MBW protocol in awake children 2–6 years of age by using an age- and tracer gas-adapted
variant of our previous approach [8] and to determine the feasibility of LCI as an outcome measure of
early CF lung disease by comparison of results between participating centres and study groups.
Methods
Study design
This prospective multicentre validation study was coordinated by the Translational Lung Research Center
Heidelberg (TLRC) and conducted across five sites of the clinical trial network within the German Center
for Lung Research (DZL) in preparation of an early intervention trial in this age group (ClinicalTrials.gov
identifier: NCT03625466) [23]. The study was approved by the Ethics Committee of the University of
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Heidelberg (coordinating centre) and the local Ethics Committees of all participating sites. Following
theoretical and hands-on in-person training at a meeting at the coordinating centre, as well as hands-on
in-person training of the members of the different study teams at the different sites by the MBW
supervisor (MS), MBW measurements were performed in preschool children following a standardised
MBW protocol. The study was conducted under supervision of the central MBW laboratory, providing
central data analysis and prompt feedback for troubleshooting. Further details on MBW training can be
found in the online supplement.
Study population
Children aged 2–6 years with CF, another lung disease and pulmonary healthy controls were eligible for
enrolment in this study. Parents and children obtained detailed information on the study protocol and
parents gave their signed informed consent. Details on CFTR genotypes of patients with CF and
information on how lung disease was excluded in the healthy control group are available in the online
supplement.
Multiple-breath washout test
N2-MBW investigations in preschool children were established at the Airway Research Center North
(ARCN), the Biomedical Research in Endstage and Obstructive Lung Disease (BREATH) centre and the
TLRC before the start of this study (“experienced centres”), and were established at the Universities of
Giessen and Marburg Lung Center (UGMLC) and the CF Center at Charité – Universitätsmedizin Berlin
as part of this study (“unexperienced centres”) [10, 24]. Technical MBW procedures were compliant with
the American Thoracic Society Technical Statement and were performed in awake, upright sitting children
with the commercially available mainstream ultrasonic flowmeter Exhalyzer D and spiroware 3.2.1 as
acquisition software (Eco Medics, Duernten, Switzerland) with N2 as tracer gas [10, 11, 22, 25]. Children
were distracted by a video while breathing through a mouthpiece with a nose clip in place. The MBW
procedure was performed following the same standard operating procedure at all centres. For this study,
each MBW attempt is called “measurement” and the collection of all measurements of a patient at one
time point is called “investigation”. Therefore, a successful MBW investigation consists of a minimum of
two successful measurements. Repeated investigation of the same patient at different time points was
allowed. Additional information on MBW testing can be found in the online supplement.
Statistical analysis
Data were analysed using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) and are shown as mean±SD,
median (range) or percentage, if not indicated otherwise. For categorical data, groups were compared with
Fisher’s exact test and for continuous data with Kruskal–Wallis test followed by the Dunn–Bonferroni
approach. Associations between LCI and continuous data were assessed by scatter plot and linear
regression with determination of the Pearson correlation coefficient. A linear regression model was used to
explain the association between age and success rate of MBW. A p-value of<0.05 was accepted to indicate
statistical significance. The upper limit of normal of the LCI was defined as the mean of the control
children+1.96×SD of these children, resulting in a value of 8.3.
Results
Demographics of the study population
In total, 74 preschool children (mean age at investigation 4.60±0.91 years; range 2.86–6.99 years),
including 46 patients with CF, 13 patients with other lung diseases and 15 healthy controls were
prospectively recruited. Other lung diseases included history of recurrent wheeze (n=9), primary ciliary
dyskinesia (n=3), and status after oesophageal atresia with tracheo-oesophageal fistula (n=1). Patients with
CF and other lung diseases showed comparable demographics to controls (table 1). Overall,
anthropometry of all three groups was on average in the normal range.
Overall feasibility of multicentre MBW in preschool children
We performed 91 N2-MBW investigations in these awake preschool children across five study sites to
determine the feasibility of multicentre preschool MBW (table 1). Each site investigated at least one control
child with an overall success rate of 93.3% (figure 1). The success rate in children with CF was 77.8%. The
success rate in children with other lung disease was comparable to that in controls (92.3%). The trend
towards a lower success rate in children with CF compared to the other groups was not significant
(p=0.218). For the complete study population, the success rate was 82.4% (figure 1). Comparison of the total
number of MBW measurements across study sites revealed no differences except a higher number of
attempts at UGMLC compared to BREATH and TLRC (Supplemental Table E2). Combined analysis of the
average number of measurements per MBW investigation of the unexperienced sites (UGMLC, Berlin) versus
the experienced sites (ARCN, BREATH, TLRC) revealed a higher number of attempts to achieve a
https://doi.org/10.1183/23120541.00408-2020 3
CYSTIC FIBROSIS | M. STAHL ET AL.
TABLE 1 Demographics of study population
All Controls CF Other lung diseases
Number of children/investigations n/n 74/91 15/15 46/63 13/13
Experienced centres:
ARCN 17/17 3/3 4/4 10/10
BREATH 18/21 5/5 13/16 0/0
TLRC 21/24 3/3 17/20 1/1
Unexperienced centres:
UGMLC 4/12 1/1 3/11 0/0
Berlin 14/17 3/3 9/12 2/2








Sex males/females n/n 31/43 6/9 18/28 7/6
Weight z-score at investigation −0.2±0.8 −0.1±0.7 −0.3±0.8 0.1±0.9
Height z-score at investigation −0.4±1.4 0.1±1.0 −0.5±1.3 −0.4±2.0
BMI z-score at investigation −0.2±1.0 −0.3±0.8 −0.2±1.0 0.4±1.0
F508del/F508del n (%) 35 (76.1)
F508del/other n (%) 8 (17.4)
Compound-heterozygous other n (%) 3 (6.6)
Pancreatic insufficiency n (%) 44 (95.7)
Data are presented as mean±SD, unless otherwise stated. Sex, genotype and exocrine pancreatic function are depicted in relation to the
individual patient; age, anthropometry and colonisation with Pseudomonas aeruginosa are displayed in relation to the time of the individual
investigation. CF: cystic fibrosis; ARCN: CF Center at Airway Research Center North; BREATH: CF Center at Biomedical Research in Endstage
and Obstructive Lung Disease Hannover; TLRC: CF Center at Translational Lung Research Center Heidelberg; UGMLC: CF Center at





























































































































FIGURE 1 Success rates of multicentre MBW investigations in awake preschool children without lung disease (control), with CF and with other
lung diseases. Summary of success rates for technically acceptable MBW investigations for the total study population and for individual study
sites. MBW: multiple-breath washout; CF: cystic fibrosis; ARCN: CF Center at Airway Research Center North; BREATH: CF Center at Biomedical
Research in Endstage and Obstructive Lung Disease Hannover; TLRC: CF Center at Translational Lung Research Center Heidelberg; UGMLC: CF
Center at Universities of Giessen and Marburg Lung Center; Berlin: CF Center at Charité - Universitätsmedizin Berlin.
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comparable number of successful MBW measurements (p=0.91) and number of successful investigations
(p=0.08) at the unexperienced sites (table 2). There was no difference between controls, children with CF or
other lung diseases concerning the number of performed and successful measurements (table 2).
Feasibility of the first MBW investigation in preschool children
To control for a possible learning effect in eight study participants with repeated investigations (three
patients with two, each two patients with three and four and one patient with five investigation time
points), we performed the same analysis taking into account the first MBW investigation of each
participant in this study only (table 3, Supplemental Table E3). Again, the number of MBW measurements
performed per investigation was higher at the unexperienced sites compared to the experienced sites to
achieve a comparable number of successful measurements (p=0.88) and successful investigations (p=0.12).
As for all investigations, the average number of performed and successful measurements was comparable
between controls, children with CF or other lung diseases when analysis was based on the first MBW
investigation of each participant in this study (table 3, supplemental table E3).
Age dependency of feasibility of MBW in preschool children
Across all centres, feasibility of MBW was 50% in 2-year-old children (2 of 4 investigations) and the
percentage of successful MBW investigations increased continuously to 90.6% (29 of 32 investigations) at
TABLE 2 Success rates of MBW investigations in awake preschool children




















All Experienced 62 3.8±1.6** 2.1±0.8 58 (93.5) 54 (87.1)
Unexperienced 29 5.2±2.5 2.1±1.3 24 (82.8) 21 (72.4)
Controls Experienced 11 4.2±2.1 2.1±0.5* 11 (100.0) 10 (90.9)
Unexperienced 4 5.5±1.9 3.0±0.8 4 (100.0) 4 (100.0)
CF Experienced 40 3.7±1.7* 1.9±0.9 36 (90.0) 33 (82.5)
Unexperienced 23 5.3±2.6 2.0±1.2 19 (82.6) 16 (69.6)
Other lung
diseases
Experienced+ 11 3.8±0.8 2.7±0.5 11 (100.0) 11 (100.0)
Unexperienced§ 2 3.0±1.4 1.5±2.1 1 (50.0) 1 (50.0)
Experienced centres are the CF Center at Airway Research Center North, the CF Center at Biomedical Research in Endstage and Obstructive
Lung Disease Hannover, and the CF Center at Translational Lung Research Center Heidelberg. Unexperienced centres are the CF Center at
Universities of Giessen and Marburg Lung Center and the CF Center at Charité - Universitätsmedizin Berlin. MBW: multiple-breath washout;
CF: cystic fibrosis. *: p<0.05 and **: p<0.01 versus unexperienced centres; +: limited to the CF Center at Airway Research Center North and the
CF Center at Translational Lung Research Center Heidelberg; §: limited to the CF Center at Charité - Universitätsmedizin Berlin.
TABLE 3 Success rates of only the first MBW investigation in this study in awake preschool children








All Experienced 56 3.9±1.7* 2.1±0.8 49 (87.5)
Unexperienced 18 5.4±2.9 2.1±1.3 13 (72.2)
Controls Experienced 11 4.2±2.1 2.1±0.5* 10 (90.9)
Unexperienced 4 5.5±1.9 3.0±0.8 4 (100.0)
CF Experienced 34 3.8±1.8 1.9±0.9 28 (82.4)
Unexperienced 12 5.8±3.3 1.8±1.3 8 (66.7)
Other lung
diseases
Experienced¶ 11 3.8±0.8 2.7±0.5 11 (100.0)
Unexperienced+ 2 3.0±1.4 1.5±2.1 1 (50.0)
Experienced centres are the CF Center at Airway Research Center North, the CF Center at Biomedical Research in Endstage and Obstructive
Lung Disease Hannover, and the CF Center at Translational Lung Research Center Heidelberg. Unexperienced centres are the CF Center at
Universities of Giessen and Marburg Lung Center and the CF Center at Charité - Universitätsmedizin Berlin. MBW: multiple-breath washout;
CF: cystic fibrosis. *: p<0.05 versus unexperienced centres; ¶: limited to the CF Center at Airway Research Center North and the CF Center at
Translational Lung Research Center Heidelberg; +: Limited to the CF Center at Charité - Universitätsmedizin Berlin.
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the age of 5 years (figure 2). The percentage of preschool children with a successful MBW investigation
significantly correlated with age at investigation (r=0.97, p<0.01). The regression coefficient indicated an
increase in the success rate of 11.9±1.6% with every year of life.
Reasons for unsuccessful MBW measurements
Overall, 91 MBW investigations were performed in this study. Of these, 20 (22.0%) MBW investigations
consisted of measurements that were all acceptable. Fifty-five (60.4%) MBW investigations consisted of at
least two MBW measurements fulfilling quality criteria and were thus rated as successful MBW
investigation, but further MBW measurements of the same investigation did not meet acceptability criteria.
The remaining 16 (17.6%) MBW investigations were rated as unsuccessful because they had less than two
MBW measurements fulfilling quality criteria (figure 1). The main reasons for unsuccessful MBW
measurements were leaks, not meeting end of test criteria and an irregular breathing pattern. Further
reasons for unsuccessful measurements are listed in table 4.
Multicentre MBW in preschool children with CF, other lung diseases and controls
In control preschoolers, the median LCI was 7.3 (table 5, supplemental table E4, figure 3) without
significant differences in LCI between controls from different sites (p=0.38), in the coefficient of variation
(CV) of the LCI between different sites (p=0.56), or in the frequency of children with an abnormal LCI

























2 3 4 5 6
FIGURE 2 Multiple-breath washout (MBW) success rates according to age. MBW investigations are grouped
according to the age of the children at time of investigation, where “2” stands for the age group of children
from 2.0 to 2.9 years of age and so on. The Pearson correlation coefficient r and p-values are provided.
TABLE 4 Reasons and frequencies of unsuccessful MBW measurements
Finding in individual measurements Unsuccessful MBW
investigations, n=16
Successful MBW investigations with at least
1 unacceptable measurement, n=55
Leak 5 (31.3) 27 (49.1)
End of test criteria not met 2 (12.5) 10 (18.2)
Irregular breathing pattern 2 (12.5) 5 (9.1)
End of test criteria not met/irregular breathing pattern 2 (12.5) 4 (7.3)
Leak/end of test criteria not met 1 (6.3) 3 (5.5)
Leak/end of test criteria not met / irregular breathing pattern 2 (12.5) 1 (1.8)
End of test criteria not met/no washout started 0 (0.0) 2 (3.6)
Leak/irregular breathing pattern 1 (6.3) 0 (0.0)
Leak/swallow at critical time point 0 (0.0) 1 (1.8)
Leak/no washout started 0 (0.0) 1 (1.8)
No washout started 0 (0.0) 1 (1.8)
Use of wrong DSR set 1 (6.3) 0 (0.0)
Data are presented as n (%). MBW: multiple-breath washout; DSR: dead space reducer.
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p<0.01) (table 5, supplemental table E4, figure 3) and significantly more children with CF had an
abnormal LCI compared to controls (table 5, supplemental table E4; p<0.05). There were no significant
differences in LCI between children with CF from different sites (p=0.11), in CV of the LCI between sites
(p=0.65) and in the frequency of CF patients with abnormal LCI at different sites (p=0.76). The median
LCI of preschool children with other lung diseases (7.9) was comparable to children with CF (p=0.95) and
tended to be increased compared to controls, but this trend did not reach statistical significance (p=0.057)
(table 5, figure 3). Of note, the two preschool children with other lung diseases with the highest LCI values
were those patients with primary ciliary dyskinesia (figure 3).
TABLE 5 Distribution of LCI between study sites in preschool children
Diagnosis Total Experienced centres Unexperienced centres
Control Number of children 14 10 4
LCI, median (range) 7.3 (6.5–8.3) 7.2 (6.5–7.8) 7.5 (7.2–8.3)
LCICV, median (range), % 2.8 (0.0–10.7) 4.2 (0.0–10.7) 2.2 (2.0–7.1)
Investigations with abnormal LCI, n (%) 1 (7.1) 0 (0.0) 1 (25.0)
CF Number of children 49 33 16
LCI, median (range) 8.2 (6.7–15.5)** 8.2 (6.7–11.3)** 8.4 (6.8–15.5)
LCICV, median (range), % 4.2 (0.3–17.1) 4.0 (0.3–8.9) 4.2 (0.7–17.1)
Investigations with abnormal LCI, n (%) 23 (46.9)** 14 (42.2)* 9 (56.3)
Other lung diseases Number of children 12 11 1
LCI, median (range)+ 7.9 (6.6–13.9) 7.4 (6.6–13.9) 11.1
LCICV, median (range), %
+ 2.6 (0.6–8.4) 2.3 (0.6–8.4) 5.2
Investigations with abnormal LCI, n (%) 6 (50.0)** 5 (45.5) 1 (100.0)
Experienced centres are the CF Center at Airway Research Center North, the CF Center at Biomedical Research in Endstage and Obstructive
Lung Disease Hannover, and the CF Center at Translational Lung Research Center Heidelberg. Unexperienced centres are the CF Center at
Universities of Giessen and Marburg Lung Center and the CF Center at Charité - Universitätsmedizin Berlin. LCI: lung clearance index; CF:
cystic fibrosis; CV: coefficient of variation. *: p<0.05 and **: p<0.01 versus control; +: in case of a single investigation, the result of this











Control CF Other lung diseases
FIGURE 3 Summary of lung clearance index (LCI) in preschool children without lung disease (control), with
cystic fibrosis (CF) and with other lung diseases in the multicentre setting. Dotted line represents upper limit
of normal of 8.3. Open circles (CF Center at Airway Research Center North), closed circles (CF Center at
Biomedical Research in Endstage and Obstructive Lung Disease Hannover), open triangles (CF Center at
Translational Lung Research Center Heidelberg), closed triangles (CF Center at Universities of Giessen and
Marburg Lung Center) and open squares (CF Center at Charité - Universitätsmedizin Berlin) represent data
from individual children from the respective study site. Solid horizontal lines represent median values for
each group. **: p<0.01 versus control group.
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Discussion
This study demonstrates that multicentre N2-MBW is feasible in awake preschool children with CF and
other lung diseases with high success rates using a mouthpiece as interface. In addition, we show that the
frequency and range of early ventilation inhomogeneity detected by multicentre MBW is comparable to
previous single- and multicentre studies in preschool children with CF [10, 11]. Further, this study
demonstrates that multicentre MBW can be established successfully in a clinical trial network including
study sites without prior experience in MBW in this challenging age group. Our results support LCI as a
promising noninvasive quantitative outcome measure for monitoring of early abnormalities in lung
function in multicentre surveillance studies, as well as early intervention clinical trials in preschool
children with CF.
High rates of technically acceptable MBW investigations across study groups (77–93%) and study sites
(70–94%) with an overall success rate of 82% (figure 1; table 2) could be achieved using the previously
established approach of central training, implementation of standard operating procedures and
harmonised MBW protocols in combination with continuous supervision and central MBW analysis that
has been used for SF6-MBW in infants and preschool children [8]. Interestingly, the success rate tended to
be lower in children with CF (77.8%) than in those with other lung diseases (92.3%) or controls (93.3%;
figure 1). However, this trend did not reach statistical significance (p=0.218). This finding may be related
to the circumstances that children with CF were in some cases undergoing several other tests at their
appointments, limiting the time for MBW measurements and/or attention span of preschool children,
whereas the majority of children with other lung diseases and all control children attended the centres for
MBW investigations only. The two main reasons for unsuccessful MBW measurements in our study were
leaks and irregular breathing patterns. There was no difference in MBW feasibility if either all MBW
investigations including repeat studies in the same children were included, or if the analysis was based on
the first MBW investigation in each child only. This may be explained by the fact that at the experienced
sites that performed N2-MBW in this age group for diagnostics before start of this study, the first MBW
investigation taking place as part of this study in a participant may not have been the overall first MBW
investigation in this child. Therefore, some children may have been more advanced on their learning curve
on MBW performance, as have been the MBW operators at these sites. Further, the majority of repeated
investigations (64.7%) was performed at the two centres that were previously naïve to the performance of
N2-MBW in this age group. The number of investigations at these sites may in part have been driven by
the MBW operators for training purposes rather than the ability of the child to perform the test, leading to
a consistently higher number of MBW measurements that were performed per MBW investigation,
regardless whether this was the first investigation in a child or the third. However, it is encouraging that
with more experience, a lower number of MBW measurements per investigation was needed to achieve a
successful investigation.
Compared to the MBW success rate of our study, a recent single centre study using SF6-MBW in
un-sedated preschool children with and without various lung diseases demonstrated that success rates of
MBW investigations were highly age-dependent and very low (0–33%) in un-sedated children under the
age of 3 years [26]. As reported in this study [26], we found a strong correlation between age at
investigation and success rates of MBW investigations in preschool children, however, the rate of successful
MBW investigations in 2-year-old children was substantially higher in our study (50%). In all 2-year-old
children included in our study, MBW in this study was their first MBW investigation. While the number
of children in this age group was limited in our study (n=4), it is promising that two of these young
preschoolers were already able to perform successful MBW investigations. We speculate that this higher
success rate may be attributable to the research setting in our study (with probably more time per MBW
investigation) compared to the routine outpatient setting in the study by DOWNING and colleagues [26].
The success rates in the older preschool age groups of our study is comparable to the high success rate of
>70% in the previous study using SF6-MBW (figure 2) [26]. This is of special interest as the typical age
range for paediatric investigation plans for clinical trials in children is 2–5 years of age [27]. Therefore, it
seems possible to include at least some 2-year-old children in trials assessing safety and efficacy across the
age range of 2–5 years.
Compared to our study, the SHIP study being the largest interventional study that used the change in LCI
as primary end-point in preschool children with CF to date reported a slightly higher overall success rate
of 89% [17]. This may be explained by several differences compared to our study including: 1) up to six
repeated investigations per patient in the SHIP study, which may have led to a learning effect in the
children; 2) the use of a face mask as interface, which may be easier for children to perform MBW; and 3)
inclusion of children from the age of 3 years instead of 2 years as in our study [17].
Another recent study investigated the feasibility of N2-MBW in preschool children comparing two
interfaces, mouthpiece and face mask [28]. In that study, the success rate in children under the age of
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4 years using a mouthpiece was <30% [28]. In comparison, the success rate in children under 4 years of
age was 68.0% (17 of 24 investigations) and therefore substantially higher in our study (figure 2). As the
settings for MBW investigation using the mouthpiece were rather comparable in our study and the study
by ROBINSON and colleagues [28] with an adequate period for each child, we speculate that the number of
MBW measurements per investigation may have been higher in our study, while it was not reported in the
previous study [28]. If a face mask was used in the former study, the success rate in children under the age
of 4 years was 85% and reached rates of 90–100% in older preschool children that were comparable to the
results of our study in these age groups using a mouthpiece (figure 2) [28]. While there are advantages
and disadvantages of both interfaces in the preschool age range that have been discussed elsewhere [22],
the reason for using the mouthpiece in our study on feasibility of multicentre MBW was the preparation
of a randomised-controlled trial with repeated MBW investigations over a trial duration of 2 years in
preschool children with CF aged 2–5 years at screening (ClinicalTrials.gov identifier: NCT03625466).
Therefore, we decided to avoid the possible influence of a changing interface dead space following growth
and development of the facial features over time when using a facemask on MBW outcomes, and used a
mouthpiece with nose clip instead. Our approach may require a longer training phase of the children to
ensure breathing stability and leak-free sealing around the mouthpiece, but these efforts will pay off in
observational studies over several years where comparable MBW settings are a pre-requisite for
longitudinal analysis of lung function.
Besides the role of LCI in surveillance of lung disease and its use to investigate response to therapy in
patients with CF, MBW gains increasing attention for monitoring of lung function in other childhood
lung disease such as asthma or PCD [29, 30]. In this context, the high success rate of MBW measurements
in preschool children with other lung diseases (figure 1) and detection of substantially elevated LCI values
in the two children with PCD participating in our study is encouraging and provides initial support of LCI
as promising noninvasive quantitative outcome measure in other early-onset lung diseases in children
(figure 3).
A limitation of this study is the unknown transferability of the high MBW success rates obtained in our
study conducted in the well-equipped translational research network of the DZL with experienced clinical
research personnel and lung function laboratories at each study site. Feasibility and transferability of our
results to a broader multicentre clinical trial setting may be strongly influenced by the established
infrastructure. Recent studies on the effect of inhaled hypertonic saline and CFTR modulators in preschool
children at sites highly experienced in preschool MBW using LCI as an end-point support transferability
of our results to multicentre clinical trials [17, 31]. However, replication studies in larger networks, such as
the ECFS-Clinical Trial Network or the CF Therapeutics Development Network, will be necessary to
determine whether our findings can be replicated in other trial networks before LCI can be used as a
widespread outcome measure in multicentre clinical trials in preschool children.
In summary, our results demonstrate that MBW for assessment of lung function is feasible with sufficient
success rates in awake preschool children with CF, other lung diseases and controls using a commercially
available mainstream ultrasonic flowmeter. In addition, this study shows that following initial training and
under continuous supervision by a specialised paediatric MBW core laboratory, the LCI is sensitive to
detect abnormalities of lung function in preschool children with CF in a multicentre setting. Our study
supports the use of LCI as diagnostic tool for surveillance of early lung disease, and as a potential
quantitative end-point in multicentre clinical trials testing early interventions in preschool children with
CF and possibly other early-onset lung diseases.
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